Inhibition of skin fibrosis in systemic sclerosis by botulinum toxin B via the suppression of oxidative stress.
botulinum toxin
fibroblast
oxidative stress
skin fibrosis
systemic sclerosis
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
21
03
2021
received:
02
03
2021
accepted:
23
03
2021
pubmed:
12
4
2021
medline:
6
7
2021
entrez:
11
4
2021
Statut:
ppublish
Résumé
Oxidative stress has been reported to play an important role in the pathogenesis of skin fibrosis in systemic sclerosis (SSc). We previously identified that botulinum toxin (BTX) injection suppresses pressure ulcer formation in a cutaneous ischemia-reperfusion injury mouse model by regulation of oxidative stress. However, the therapeutic possibility of BTX administration for preventing skin fibrosis in SSc is unclear. The objective of this study was to investigate the effect of BTX-B on skin fibrosis in a murine model of SSc and determine the underlying mechanism. We found that BTX-B injection significantly reduced dermal thickness and inflammatory cell infiltration in bleomycin-induced skin fibrosis lesion in mice. We also identified that the oxidative stress signal detected through bioluminescence in OKD48 mice after bleomycin injection in the skin was significantly decreased by BTX-B. Additionally, mRNA levels of oxidative stress associated factors (NOX2, HO-1, Trx2) were significantly decreased by BTX-B. Apoptotic cells in the lesional skin of bleomycin-treated mice were significantly reduced by BTX-B. Oxidant-induced intracellular accumulation of reactive oxygen species in SSc fibroblasts was also inhibited by BTX-B. In conclusion, BTX-B might improve bleomycin-induced skin fibrosis via the suppression of oxidative stress and inflammatory cells in the skin. BTX-B injection may have a therapeutic effect on skin fibrosis in SSc.
Identifiants
pubmed: 33840125
doi: 10.1111/1346-8138.15888
doi:
Substances chimiques
Bleomycin
11056-06-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1052-1061Subventions
Organisme : JSPS KAKENHI
ID : 18K16019
Informations de copyright
© 2021 Japanese Dermatological Association.
Références
Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol. 2010;6:453-60.
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685-99.
Stein CM, Tanner SB, Awad JA, Roberts LJ II, Morrow JD. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum. 1996;39:1146-50.
Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al. Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:2653-64.
Bourji K, Meyer A, Chatelus E, Pincemail J, Pigatto E, Defraigne J-O, et al. High reactive oxygen species in fibrotic and non fibrotic skin of patients with diffuse cutaneous systemic sclerosis. Free Radic Biol Med. 2015;87:282-9.
Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol. 1993;28:78-85.
Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012;6:87-95.
Luo JY, Liu X, Jiang M, Zhao HP, Zhao JJ. Oxidative stress markers in blood in systemic sclerosis: a meta-analysis. Mod. Rheumatol. 2017;27:306-14.
Motegi S, Toki S, Yamada K, Uchiyama A, Ishikawa O. Elevated plasma homocysteine level is possibly associated with skin sclerosis in a series of Japanese patients with systemic sclerosis. J Dermatol. 2014;41:986-91.
Yoshizaki A, Yanaba K, Ogawa A, Iwata Y, Ogawa F, Takenaka M, et al. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin- induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 2011;63:3086-97.
Dosoki H, Stegemann A, Taha M, Schnittler H, Luger TA, Schröder K, et al. Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Exp Dermatol. 2017;26:73-81.
Lee DH, Kang SM, Feneran A, Youn CS, Kim JK, Cho S, et al. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study. J Eur Acad Dermatol Venereol. 2013;27:1-7.
Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm (Vienna). 2008;115:607-16.
Marques RE, Duarte GS, Rodrigues FB, Castelão M, Ferreira J, Sampaio C, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016;5:CD004315.
Sekiguchi A, Motegi S-I, Uchiyama A, Uehara A, Fujiwara C, Yamazaki S, et al. Botulinum toxin B suppresses the pressure ulcer formation in cutaneous ischemia-reperfusion injury mouse model: Possible regulation of oxidative and endoplasmic reticulum stress. J Dermatol Sci. 2018;90:144-53.
Uchiyama A, Yamada K, Perera B, Ogino S, Yokoyama Y, Takeuchi Y, et al. Protective effect of botulinum toxin A after cutaneous ischemia-reperfusion injury. Sci Rep. 2015;5:9072.
Dini E, Mazzucchi S, De Luca C, Cafalli M, Chico L, Lo Gerfo A, et al. Plasma levels of oxidative stress markers, before and after BoNT/A treatment in chronic migraine. Toxins. 2019;11:608.
Motegi S-I, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016;43:56-62.
Motegi S, Uehara A, Yamada K, Sekiguchi A, Fujiwara C, Toki S, et al. Efficacy of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol. 2017;97:843-50.
Yokoyama Y, Sekiguchi A, Fujiwara C, Uchiyama A, Uehara A, Ogino S, et al. Inhibitory regulation of skin fibrosis in systemic sclerosis by Apelin/APJ signaling. Arthritis Rheumatol. 2018;70:1661-72.
Fujiwara C, Uehara A, Sekiguchi A, Uchiyama A, Yamazaki S, Ogino S, et al. Suppressive regulation by MFG-E8 of latent transforming growth factor β- Induced fibrosis via binding to αv integrin: significance in the pathogenesis of fibrosis in systemic sclerosis. Arthritis Rheumatol. 2019;71:302-14.
Thoua NM, Derrett-Smith EC, Khan K, Dooley A, Shi-Wen X, Denton CP, et al. Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology. 2012;51:1989-98.
Oikawa D, Akai R, Tokuda M, Iwawaki T. A transgenic mouse model for monitoring oxidative stress. Sci Rep. 2012;2:229.
Motegi S-I, Sekiguchi A, Uchiyama A, Uehara A, Fujiwara C, Yamazaki S, et al. Protective effect of mesenchymal stem cells on the pressure ulcer formation by the regulation of oxidative and endoplasmic reticulum stress. Sci Rep. 2017;7:17186.
Uchiyama A, Yamada K, Perera B, Ogino S, Yokoyama Y, Takeuchi Y, et al. Protective effect of MFG-E8 after cutaneous ischemia-reperfusion injury. J Invest Dermatol. 2015;135:1157-65.
LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-5.
Motegi S, Uchiyama A, Yamada K, Ogino S, Yokoyama Y, Perera B, et al. Increased susceptibility to oxidative stress- and ultraviolet A-induced apoptosis in fibroblasts in atypical progeroid syndrome/atypical Werner syndrome with LMNA mutation. Exp Dermatol. 2016;25:20-7.
Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245-313.
Tanaka T, Hosoi F, Yamaguchi-Iwai Y, Nakamura H, Masutani H, Ueda S, et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J. 2002;21:1695-703.
Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem. 1999;274:26071-8.
Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res. 2006;297:333-44.
Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol. 2005;14:81-95.
Borodic GE, Acquadro M, Johnson EA. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001;10:1531-44.
Yoo KY, Lee HS, Cho YK, Lim YS, Kim YS, Koo JH, et al. Anti-inflammatory effects of botulinum toxin type A in a complete Freund’s adjuvant-induced arthritic knee joint of hind leg on rat model. Neurotox Res. 2014;26:32-9.
Amalia SN, Uchiyama A, Baral H, Inoue Y, Yamazaki S, Fujiwara C, et al. Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system. J Dermatol Sci. 2021;101:58-68.
Tsou P-S, Talia NN, Pinney AJ, Kendzicky A, Piera-Velazquez S, Jimenez SA, et al. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts. Arthritis Rheum. 2012;64:1978-89.
Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65:1953-62.
Grygiel-Gorniak B, Puszczewicz M. Oxidative damage and antioxidative therapy in systemic sclerosis. Mediators Inflamm. 2014;389582:1-11.
Shroff A, Mamalis A, Jagdeo J. Oxidative stress and skin fibrosis. Curr Pathobiol Rep. 2014;2:257-67.
Svegliati S, Cancello R, Sambo P, Luchetti M, Paroncini P, Orlandini G, et al. Platelet-derived growth factor and reactive oxygen species regulate Ras protein levels in primary human fibroblasts via ERK1/2: amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem. 2005;280:36474-82.
Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, et al. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the WNT inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal. 2014;7:ra84.
Herrick AL, Matucci CM. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol. 2001;19:4-8.
Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology. 2001;155:1-15.
Dooley A, Shi-Wen X, Aden N, Tranah T, Desai N, Denton CP, et al. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3- gallate. Rheumatology. 2010;49:2024-36.
Toyama T, Looney AP, Baker BM, Stawski L, Haines P, Simms R. Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J Invest Dermatol. 2018;138:78-88.
Sekiguchi A, Motegi S-I, Fujiwara C, Yamazaki S, Inoue Y, Uchiyama A, et al. Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress. J Dermatol Sci. 2019;96:8-17.
Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthetic Plast Surg. 2010;34:424-7.
Xiao Z, Qu G. Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules. 2012;17:2169-77.
Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33:409-12.
Jeong HS, Lee BH, Sung HM, Park SY, Ahn DK, Jung MS, et al. Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg. 2015;136:171-8.
Kim S, Ahn M, Piao Y, Ha Y, Choi D-K, Yi M-H, et al. Effect of botulinum toxin type A on TGF-β/Smad pathway signaling: implications for silicone-induced capsule formation. Plast Reconstr Surg. 2016;138:821-9.
Hoverson K, Love T, Lam TK, Marquart JD. A novel treatment for limited mouth opening due to facial fibrosis: a case series. J Am Acad Dermatol. 2018;78:190-2.
Ponzo MG, Carruthers A, Humphrey S. Corrective hyaluronic acid fillers and combination cosmetic treatments for facial cutaneous defects due to autoimmune connective tissue diseases: a retrospective review. Dermatol Surg. 2017;43:1510-3.
Spadoni T, Svegliati Baroni S, Amico D, Albani L, Moroncini G, Avvedimento EV, et al. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol. 2015;67:1611-22.
Amico D, Spadoni T, Rovinelli M, Serafini M, D’Amico G, Campelli N, et al. Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: role of NADPH oxidase and ERK1/2. Arthritis Res Ther. 2015;17:68.
Jiang M, Yu Y, Luo J, Gao Q, Zhang L, Wang Q, et al. Bone marrow-derived mesenchymal stem cells expressing thioredoxin 1 attenuate bleomycin- induced skin fibrosis and oxidative stress in scleroderma. J Invest Dermatol. 2017;137:1223-33.
Schweizer DF, Schweizer R, Zhang S, Kamat P, Contaldo C, Rieben R, et al. Botulinum toxin A and B raise blood flow and increase survival of critically ischemic skin flaps. J Surgical Res. 2013;184:1205-13.
Wu X, Zhang YU, Chen L, Han Y, Song Y, Cheng H, et al. BTX-A promotes expression of angiogenesis-associated genes in human umbilical vein endothelial cells. DNA Cell Biol. 2020;39:2154-65.